G2MC WORKING GROUPS

Evidence

Monitoring and promoting awareness of evidence that supports genomic medicine. 

Overview

CO-LEADS

Marc Abramowicz (Belgium)
Fahd Al-Mulla (Kuwait)

MISSION

The Evidence Working Group aims to monitor evidence of the clinical utility of genomic medicine and to promote awareness about current evidence available to support genomic medicine. The ultimate goal is to promote the implementation of genomic medicine worldwide, including in low and middle income countries.

GOALS

  • Define criteria for evidence evaluation (e.g., standard definition of a patient’s outcomes).
  • Monitor evidence of clinical utility of genomic medicine. Actively monitor emerging evidence.
  • Develop a genomic medicine implementation registry for evidence generation.
  • Develop measures that can be used across the global community for harmonization and interoperability of data (e.g., phenome; genome, missing data) for evidence-generation studies.
  • Promote awareness about the evidence available to support genomic medicine; promote implementation in low and middle income countries.

Publications

WORKING GROUP PUBLICATIONS

Kumuthini, J., Zick, B., Balasopoulou, A. et al. The clinical utility of polygenic risk scores in genomic medicine practices: a systematic reviewHum Genet (2022). https://doi.org/10.1007/s00439-022-02452-x

Questions, feedback, interested in getting involved? Contact us using the form below.